ReviewMediterranean journal of hematology and infectious diseases2024
Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems.
Review in Mediterranean journal of hematology and infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07160270 (Neuropathy in Waldenström's Macroglobulinemia), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neuropathy in Waldenström's Macroglobulinemia: Pathophysiology, Prognosis and Treatment
Who cites it
10 citing papers in PubMed.
- Analytical interference by IgM paraprotein causing platform-dependent electrolyte discrepancies: a case-based laboratory investigation.Biochemia medica · 2026Article
- Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions.International journal of molecular sciences · 2026Review
- MAGa: Monoclonal Autoimmune Gammopathies.Cancers · 2026Review
- An Atypical Presentation of Ecthyma Gangrenosum in a Patient With Waldenström Macroglobulinemia.Cureus · 2026Article
- A case of transformation of Waldenström's Macroglobulinemia to diffuse large B cell lymphoma.Oxford medical case reports · 2026Article
- Waldenström macroglobulinemia-associated renal AL amyloidosis: a case report and literature review.Frontiers in immunology · 2026Review
- Background and Clinical Features of a Unique and Mysterious Autoinflammatory Disease, Schnitzler Syndrome.International journal of molecular sciences · 2025Review
- Fatal long-term complications due to bendamustine for Waldenstrom's macroglobulinemia.Clinics (Sao Paulo, Brazil) · 2025Article
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy.Mediterranean journal of hematology and infectious diseases · 2025Review
- Monoclonal Gammopathy of Neurological Significance: A Case Report and Insights on Treatment.Mediterranean journal of hematology and infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Waldenström macroglobulinemia (WM) is an infrequent variant of lymphoma, classified as a B-cell malignancy identified by the presence of IgM paraprotein, infiltration of clonal, small lymphoplasmacytic B cells in the bone marrow, and the MYD88 L265P mutation, which is observed in over 90% of cases. The direct invasion of the malignant cells into tissues like lymph nodes and spleen, along with the immune response related to IgM, can also lead to various health complications, such as cytopenias, hyperviscosity, peripheral neuropathy, amyloidosis, and Bing-Neel syndrome. Chemoimmunotherapy has historically been considered the preferred treatment for WM, wherein the combination of rituximab and nucleoside analogs, alkylating drugs, or proteasome inhibitors has exhibited notable efficacy in inhibiting tumor growth. Recent studies have provided evidence that Bruton Tyrosine Kinase inhibitors (BTKI), either used independently or in conjunction with other drugs, have been shown to be effective and safe in the treatment of WM. The disease is considered to be non-curable, with a median life expectancy of 10 to 12 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.